Two Case Reports of Huntington Disease in One Family and Literature Review
Department of Neurology,Dalian Municipal Central Hospital,Dalian 116033,China
*Corresponding author:WANG Suping,Chief physician; E-mail:wangsuping@medmail.com
[1]中华医学会神经病学分会帕金森病及运动障碍学组.亨廷顿病的诊断与治疗指南[J].中华神经科杂志,2011,44(9):638-641.DOI:10.3760/cma.J.issn.1006-7876.2011.09.017.
Parkinson's Disease and Dyskinesia Group,Society of Neurology,Chinese Medical Association.Guidelines for diagnosis and treatment of Huntington disease[J].Chinese Journal of Neurology,2011,44(9):638-641.DOI:10.3760/cma.J.issn.1006-7876.2011.09.017.
[2]BATES G,HARPER P,JONES L.Huntington's disease[M].3rd ed.United Kingdom:Oxford University Press,2002.
[3]GUSELLA J F,WEXLER N S,CONNEALLY P M,et al.A polymorphic DNA marker genetically linked to Huntington's disease[J].Nature,1983,306(5940):234-238.
[4]The Huntington's Disease Collaborative Research Group.A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes[J].Cell,1993,72(6):971-983.
[5]LOI S M,WALTERFANG M,VELAKOULIS D,et al.Huntington's disease:managing neuropsychiatric symptoms in Huntington's disease[J].Australas Psychiatry,2018,26(4):376-380.DOI:10.1177/1039856218766120.
[6]DICKEY A S,LA SPADA A R.Therapy development in Huntington disease:from current strategies to emerging opportunities[J].Am J Med Genet A,2018,176(4):842-861.DOI:10.1002/ajmg.a.38494.
[7]RUé L,BA?EZ-CORONEL M,CREUS-MUNCUNILL J,et al.Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels[J].J Clin Invest,2016,126(11):4319-4330.DOI:10.1172/JCI83185.
[8]DUBINSKY J M.Towards an understanding of energy impairment in Huntington's disease brain[J].J Huntingtons Dis,2017,6(4):267-302.DOI:10.3233/JHD-170264.
[9]张宝荣,宋飞,殷鑫浈,等.两个亨廷顿舞蹈病家系IT15基因的研究[J].遗传,2006,28(11):1345-1349.DOI:10.3321/j.issn:0253-9772.2006.11.002.
ZHANG B R,SONG F,YIN X Z,et al.IT15 gene analysis in two pedigrees of Huntington's disease[J].Hereditas,2006,28(11):1345-1349.DOI:10.3321/j.issn:0253-9772.2006.11.002.
[10]POON L H,KANG G A,LEE A J.Role of tetrabenazine for Huntington's disease-associated chorea[J].Ann Pharmacother,2010,44(6):1080-1089.DOI:10.1345/aph.1M582.
[11]CUBO E,SHANNON K M,TRACY D,et al.Effect of donepezil on motor and cognitive function in Huntington disease[J].Neurology,2006,67(7):1268-1271.DOI:10.1212/01.wnl.0000238106.10423.00.
[12]CARMO C,NAIA L,LOPES C,et al.Mitochondrial dysfunction in Huntington's disease[J].Adv Exp Med Biol,2018,1049:59-83.DOI:10.1007/978-3-319-71779-1_3.
[13]RUZO A,CROFT G F,METZGER J J,et al.Chromosomal instability during neurogenesis in Huntington's disease[J].Development,2018,145(2):156844.DOI:10.1242/dev.156844.
[14]GARRET M,DU Z,CHAZALON M,et al.Alteration of GABAergic neurotransmission in Huntington's disease[J].CNS Neurosci Ther,2018,24(4):292-300.DOI:10.1111/cns.12826.
[15]GóMEZ-PINEDA V G,TORRES-CRUZ F M,VIVAR-CORTéS C I,et al.Neurotrophin-3 restores synaptic plasticity in the striatum of a mouse model of Huntington's disease[J].CNS Neurosci Ther,2018,24(4):353-363.DOI:10.1111/cns.12824.
[16]SIMMONS D A.Modulating neurotrophin receptor signaling as a therapeutic strategy for Huntington's disease[J].J Huntingtons Dis,2017,6(4):303-325.DOI:10.3233/JHD-170275.
[17]RIDOLFI B,ABDEL-HAQ H.Neurodegenerative disorders treatment:the microRNA role[J].Curr Gene Ther,2017,17(5):327-363.DOI:10.2174/1566523218666180119120726.
[18]REED E R,LATOURELLE J C,BOCKHOLT J H,et al.MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study[J].Neurology,2018,90(4):e264-272.DOI:10.1212/WNL.0000000000004844.
[19]FRANICH N R,FITZSIMONS H L,FONG D M,et al.AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease[J].Mol Ther,2008,16(5):947-956.DOI:10.1038/mt.2008.50.
[20]CONNOR B.Concise review:the use of stem cells for understanding and treating Huntington's disease[J].Stem Cells,2018,36(2):146-160.DOI:10.1002/stem.2747.